CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

DataM Intelligence | competitive Intelligence Explore the evolving Multiple Myeloma market: drug innovations, emerging therapies, and key p ...

New research presented by Noella Collado-Gisbert reveals that tracking residual disease kinetics in multiple myeloma predicts ...

A panelist discusses the latest advancements presented at ASCO 2025, highlighting talquetamab’s pivotal trial in relapsed/refractory multiple myeloma that demonstrated high response rates and longer ...

Final results from the Phase II CONCEPT trial reveal that isatuximab combined with carfilzomib, lenalidomide, and ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D ...